Clinical Assessment of Insulin Fast Dissolving Film in Treatment of Post Infection Anosmia : "Insulin Fast Dissolving Film for Intranasal Delivery Via Olfactory Region, a Promising Approach for the Treatment of Anosmia in COVID 19 Patients: Design, In-vitro Characterization and Clinical Evaluation."
This study was designed to improve smell disorders after corona infection that is very anxious for all patients.Inclusion criteria were loss of smell, post covid-19 infection, age from 18 to 70 years and accept sharing and follow up.The application of dosage form by ENT specialist at otorhinolaryngology clinic at Minia University hospital. Dose was 100iu of insulin 3 times weekly for 4 weeks. The new dosage form with insulin was compared with a placebo to ensure statistical improvement.The tests were performed in each visit. Primary outcome was the improvement of smell sensors in those patients.
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
ClinicalTrials.gov - (2021) vom: 26. Okt. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
610 |
|---|
| Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: December 8, 2020, Last downloaded: ClinicalTrials.gov processed this data on November 08, 2021, Last updated: November 10, 2021 |
|---|
| Study ID: |
NCT04657809 |
|---|---|
| Veröffentlichungen zur Studie: |
|
| fisyears: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
CTG003598772 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG003598772 | ||
| 003 | DE-627 | ||
| 005 | 20230425192422.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210408s2021 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG003598772 | ||
| 035 | |a (UBBS_Klinische_Studien)NCT04657809 | ||
| 035 | |a (UBBS_Klinische_Studien)S85insu23fdf | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Clinical Assessment of Insulin Fast Dissolving Film in Treatment of Post Infection Anosmia |b "Insulin Fast Dissolving Film for Intranasal Delivery Via Olfactory Region, a Promising Approach for the Treatment of Anosmia in COVID 19 Patients: Design, In-vitro Characterization and Clinical Evaluation." |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: December 8, 2020, Last downloaded: ClinicalTrials.gov processed this data on November 08, 2021, Last updated: November 10, 2021 | ||
| 520 | |a This study was designed to improve smell disorders after corona infection that is very anxious for all patients.Inclusion criteria were loss of smell, post covid-19 infection, age from 18 to 70 years and accept sharing and follow up.The application of dosage form by ENT specialist at otorhinolaryngology clinic at Minia University hospital. Dose was 100iu of insulin 3 times weekly for 4 weeks. The new dosage form with insulin was compared with a placebo to ensure statistical improvement.The tests were performed in each visit. Primary outcome was the improvement of smell sensors in those patients | ||
| 650 | 2 | |a Anosmia | |
| 650 | 4 | |a Medical Condition: Anosmia | |
| 650 | 4 | |a Study Type: Interventional | |
| 650 | 4 | |a Recruitment Status: Completed | |
| 650 | 4 | |a Phase: Phase 2 | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2021) vom: 26. Okt. |
| 773 | 1 | 8 | |g year:2021 |g day:26 |g month:10 |
| 856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT04657809 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 26 |c 10 | ||